[关键词]
[摘要]
目的 观察小金片联合NX化疗方案(长春瑞滨联合卡培他滨)治疗紫杉类及蒽环类耐药晚期乳腺癌的临床效果。方法 选取2019年1月-2020年1月南阳市第二人民医院收治的100例紫杉类及蒽环类耐药晚期乳腺癌患者,根据信封抽签法分为对照组和治疗组,每组各50例。对照组给予NX化疗方案治疗,第1、8天静脉滴注酒石酸长春瑞滨注射液,25 mg/m2;第1~14天口服卡培他滨片,1 000 mg/m2,2次/d。治疗组在对照组基础上口服小金片,2片/次,2次/d。以21 d为1个周期,两组患者共治疗4个周期。观察两组疗效,比较两组的KPS评分、细胞免疫功能指标、血清肿瘤标志物。结果 治疗后,治疗组的客观缓解率为64.00%,较对照组的44.00%更高(P<0.05)。治疗后,两组KPS评分升高(P<0.05),且治疗组KPS评分高于对照组(P<0.05)。治疗后,两组患者CD8+升高,CD3+、CD4+、CD4+/CD8+下降(P<0.05),治疗后治疗组CD8+比对照组高,CD3+、CD4+、CD4+/CD8+比对照组更低(P<0.05)。治疗后,两组癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)水平下降(P<0.05),且治疗组CEA、CA125和CA199水平比对照组更低(P<0.05)。结论 小金片联合NX化疗方案治疗紫杉类及蒽环类耐药晚期乳腺癌具有较好的疗效,可有效阻止疾病进展,提高生活质量,减轻免疫抑制,降低患者血清肿瘤标志物水平,安全较好。
[Key word]
[Abstract]
Objective To observe the clinical effect of Xiaojin Tablets combined with NX chemotherapy regimen (vinorelbine combined with capecitabine) in treatment of taxane and anthracycline resistant advanced breast cancer. Methods Patients (100 cases) with taxane and anthracycline resistant advanced breast cancer in Nanyang Second General Hospital from January 2019 to February 2020 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were given NX chemotherapy regimen. Patients in the control group were iv administered with Vinorelbine Tartrate Injection on the first and eighth day, 25 mg/m2, and patients were also po administered with Capecitabine Tablets from first to fourteenth day, 1 000 mg/m2, twice daily. Patients in the treatment group were po administered with Xiaojin Tablets on the basis of the control group, 2 tablets/time, twice daily. A course had 21 d, and patients in two groups were treated for 4 courses. After treatment, the clinical efficacies were evaluated, and KPS scores, cellular immune function indexes, and serum tumor markers in two groups were compared. Results After treatment, the objective remission rate of the treatment group was 64.00%, which was higher than objective remission rate (44.00%) of the control group (P<0.05). After treatment, the KPS score of two groups was increased (P<0.05), and the KPS score of the treatment group was higher than that of the control group (P<0.05). After treatment, the CD8+ in two groups were increased, but the CD3+, CD4+ and CD4+/CD8+ were decreased (P<0.05). After treatment, the CD8+ in treatment group was higher than that in control group, but the CD3+, CD4+, and CD4+/CD8+ in two groups were lower than those in control group (P<0.05). After treatment, the levels of CEA, CA125, and CA199 in two groups were decreased (P<0.05), and the levels of CEA, CA125, and CA199 in the treatment group were lower than those in the control group (P<0.05). Conclusion Xiaojin Tablets combined with NX chemotherapy regimen has clinical curative effect in treatment of taxane and anthracycline resistant advanced breast cancer, can effectively prevent disease progression, improve the quality of life, reduce immunosuppression, and reduce the serum level of tumor markers, with good safety.
[中图分类号]
R984;R979.1
[基金项目]
河南省医学科技攻关计划(联合共建)项目(LHGJ20191463)